A Case Series of Choroidal and Orbital Neuroendocrine Tumors: Metastasis: Two Patients Treated With Peptide Radionuclide Therapy

Pancreas. 2024 May 1;53(5):e445-e449. doi: 10.1097/MPA.0000000000002316. Epub 2024 Mar 14.

Abstract

Neuroendocrine tumors (NETs) are rare cancers with heterogeneous histologies, response to treatments, and prognoses. Majority of these cancers originate in the gastrointestinal tract and metastasize to the liver. We report the cases of 5 patients with low-grade NET disease with rare metastases to the choroids. Two of the patients were treated with peptide receptor radionuclide therapy (lutetium 177 [ 177 Lu]). This is the first report confirming peptide radionuclide therapy safety in patients with low-grade NET with ocular metastases.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aged
  • Choroid Neoplasms* / radiotherapy
  • Choroid Neoplasms* / secondary
  • Female
  • Humans
  • Lutetium / therapeutic use
  • Male
  • Middle Aged
  • Neuroendocrine Tumors* / pathology
  • Neuroendocrine Tumors* / radiotherapy
  • Neuroendocrine Tumors* / secondary
  • Orbital Neoplasms* / radiotherapy
  • Orbital Neoplasms* / secondary
  • Radioisotopes / therapeutic use
  • Radiopharmaceuticals / therapeutic use
  • Receptors, Peptide / metabolism
  • Treatment Outcome

Substances

  • Lutetium
  • Radiopharmaceuticals
  • Radioisotopes
  • Lutetium-177
  • Receptors, Peptide